GCM
SPRY icon

Graham Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Graham Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,469
Closed -$132K – 1504
2024
Q4 		$132K Buy
+12,469
New +$175K ﹤0.01% 1129

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Graham Capital Management's SPRY Position: Q1 2025 in Review

Graham Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 12,469 shares — an estimated $132K sold.

Graham Capital Management first reported a position in SPRY in Q4 2024 and held it in 1 quarter. The position peaked at $132K in Q4 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Graham Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 12,469 ARS Pharmaceuticals shares in Q1 2025, an estimated $132K.
  • Graham Capital Management first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Graham Capital Management's ARS Pharmaceuticals position peaked at $132K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.